Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples